A triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor (DSM421) with improved drug-like properties for treatment and prevention of malaria (ACS infectious diseases, 2016)

(untitled) - Phillips, M; White, K; Kokkonda, S; Deng, X; White, J; El Mazouni, F; Marsh, K; Tomchick, D; Manjalanagara, K; Rudra, K; Wirjanata, G; Noviyanti, R; et al.